annual EBITDA:
$5.32B+$624.70M(+13.31%)Summary
- As of today (June 26, 2025), REGN annual EBITDA is $5.32 billion, with the most recent change of +$624.70 million (+13.31%) on December 31, 2024.
- During the last 3 years, REGN annual EBITDA has fallen by -$4.35 billion (-45.00%).
- REGN annual EBITDA is now -45.00% below its all-time high of $9.67 billion, reached on December 31, 2021.
Performance
REGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$1.04B-$54.40M(-4.97%)Summary
- As of today (June 26, 2025), REGN quarterly EBITDA is $1.04 billion, with the most recent change of -$54.40 million (-4.97%) on March 31, 2025.
- Over the past year, REGN quarterly EBITDA has increased by +$209.70 million (+25.24%).
- REGN quarterly EBITDA is now -72.89% below its all-time high of $3.84 billion, reached on June 30, 2021.
Performance
REGN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$5.53B+$209.70M(+3.94%)Summary
- As of today (June 26, 2025), REGN TTM EBITDA is $5.53 billion, with the most recent change of +$209.70 million (+3.94%) on March 31, 2025.
- Over the past year, REGN TTM EBITDA has increased by +$979.00 million (+21.52%).
- REGN TTM EBITDA is now -42.83% below its all-time high of $9.67 billion, reached on December 31, 2021.
Performance
REGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
REGN EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +13.3% | +25.2% | +21.5% |
3 y3 years | -45.0% | -9.4% | -41.7% |
5 y5 years | +99.2% | +42.4% | +97.7% |
REGN EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -45.0% | +13.3% | -41.0% | +25.2% | -41.7% | +21.5% |
5 y | 5-year | -45.0% | +99.2% | -72.9% | +42.4% | -42.8% | +97.7% |
alltime | all time | -45.0% | +3218.6% | -72.9% | +2123.8% | -42.8% | +3341.5% |
REGN EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2025 | - | $1.04B(-5.0%) | $5.53B(+3.9%) |
Dec 2024 | $5.32B(+13.3%) | $1.09B(-32.8%) | $5.32B(-3.3%) |
Sep 2024 | - | $1.63B(-7.7%) | $5.50B(+7.7%) |
Jun 2024 | - | $1.76B(+112.3%) | $5.11B(+12.3%) |
Mar 2024 | - | $830.90M(-35.0%) | $4.55B(-3.1%) |
Dec 2023 | $4.69B(-10.8%) | $1.28B(+3.6%) | $4.69B(-3.4%) |
Sep 2023 | - | $1.23B(+2.4%) | $4.86B(-7.3%) |
Jun 2023 | - | $1.20B(+23.5%) | $5.24B(+3.0%) |
Mar 2023 | - | $975.50M(-32.4%) | $5.09B(-3.3%) |
Dec 2022 | $5.26B(-45.6%) | $1.44B(-10.8%) | $5.26B(-17.9%) |
Sep 2022 | - | $1.62B(+54.0%) | $6.41B(-4.3%) |
Jun 2022 | - | $1.05B(-8.6%) | $6.70B(-29.4%) |
Mar 2022 | - | $1.15B(-55.7%) | $9.48B(-1.9%) |
Dec 2021 | $9.67B(+135.7%) | $2.59B(+36.1%) | $9.67B(+15.4%) |
Sep 2021 | - | $1.90B(-50.4%) | $8.38B(+10.9%) |
Jun 2021 | - | $3.84B(+187.5%) | $7.56B(+60.6%) |
Mar 2021 | - | $1.33B(+2.6%) | $4.71B(+14.7%) |
Dec 2020 | $4.10B(+53.7%) | $1.30B(+20.0%) | $4.10B(+9.3%) |
Sep 2020 | - | $1.08B(+9.8%) | $3.75B(+7.3%) |
Jun 2020 | - | $987.40M(+35.1%) | $3.50B(+25.1%) |
Mar 2020 | - | $730.80M(-23.1%) | $2.80B(+4.7%) |
Dec 2019 | $2.67B(-2.2%) | $950.80M(+14.7%) | $2.67B(+9.2%) |
Sep 2019 | - | $829.20M(+191.2%) | $2.45B(+6.6%) |
Jun 2019 | - | $284.80M(-52.9%) | $2.29B(-15.2%) |
Mar 2019 | - | $604.80M(-16.7%) | $2.71B(-0.9%) |
Dec 2018 | $2.73B(+21.4%) | $726.40M(+7.0%) | $2.73B(+5.0%) |
Sep 2018 | - | $678.70M(-2.6%) | $2.60B(+2.7%) |
Jun 2018 | - | $696.60M(+10.9%) | $2.53B(+5.4%) |
Mar 2018 | - | $628.20M(+5.5%) | $2.40B(+6.7%) |
Dec 2017 | $2.25B(+56.0%) | $595.31M(-2.3%) | $2.25B(+11.0%) |
Sep 2017 | - | $609.51M(+7.6%) | $2.03B(+11.9%) |
Jun 2017 | - | $566.38M(+18.5%) | $1.81B(+15.8%) |
Mar 2017 | - | $477.90M(+28.1%) | $1.56B(+8.5%) |
Dec 2016 | $1.44B(+9.7%) | $373.18M(-5.3%) | $1.44B(+10.4%) |
Sep 2016 | - | $394.22M(+23.8%) | $1.31B(-1.6%) |
Jun 2016 | - | $318.54M(-10.5%) | $1.33B(-3.2%) |
Mar 2016 | - | $355.77M(+49.8%) | $1.37B(+4.3%) |
Dec 2015 | $1.31B(+54.4%) | $237.44M(-42.8%) | $1.31B(+2.1%) |
Sep 2015 | - | $415.24M(+14.8%) | $1.29B(+19.5%) |
Jun 2015 | - | $361.81M(+20.7%) | $1.08B(+13.7%) |
Mar 2015 | - | $299.76M(+42.6%) | $947.02M(+11.2%) |
Dec 2014 | $851.29M(+8.6%) | $210.21M(+2.5%) | $851.29M(+0.7%) |
Sep 2014 | - | $205.06M(-11.6%) | $845.21M(-4.9%) |
Jun 2014 | - | $232.00M(+13.7%) | $888.38M(+7.7%) |
Mar 2014 | - | $204.03M(-0.0%) | $825.14M(+5.2%) |
Dec 2013 | $784.02M(+57.9%) | $204.13M(-17.8%) | $784.02M(+6.6%) |
Sep 2013 | - | $248.22M(+47.1%) | $735.73M(+5.1%) |
Jun 2013 | - | $168.76M(+3.6%) | $699.71M(+11.4%) |
Mar 2013 | - | $162.91M(+4.5%) | $628.35M(+26.5%) |
Dec 2012 | $496.67M(-391.3%) | $155.83M(-26.6%) | $496.67M(+63.3%) |
Sep 2012 | - | $212.21M(+117.9%) | $304.16M(+616.0%) |
Jun 2012 | - | $97.40M(+211.9%) | $42.48M(-139.9%) |
Mar 2012 | - | $31.23M(-185.1%) | -$106.33M(-37.6%) |
Dec 2011 | -$170.53M(+125.4%) | -$36.68M(-25.9%) | -$170.53M(+21.9%) |
Sep 2011 | - | -$49.47M(-3.8%) | -$139.90M(+19.4%) |
Jun 2011 | - | -$51.42M(+56.0%) | -$117.19M(+38.9%) |
Mar 2011 | - | -$32.97M(+444.6%) | -$84.37M(+11.5%) |
Dec 2010 | -$75.66M(+36.7%) | -$6.05M(-77.4%) | -$75.66M(-24.0%) |
Sep 2010 | - | -$26.75M(+43.7%) | -$99.59M(+41.2%) |
Jun 2010 | - | -$18.61M(-23.3%) | -$70.55M(+8.2%) |
Mar 2010 | - | -$24.25M(-19.1%) | -$65.21M(+21.6%) |
Dec 2009 | -$55.37M(-4.1%) | -$29.98M(-1404.3%) | -$53.62M(+54.1%) |
Sep 2009 | - | $2.30M(-117.3%) | -$34.80M(-35.9%) |
Jun 2009 | - | -$13.27M(+4.8%) | -$54.26M(-5.9%) |
Mar 2009 | - | -$12.66M(+13.4%) | -$57.67M(-0.5%) |
Dec 2008 | -$57.74M(-29.6%) | -$11.17M(-34.9%) | -$57.97M(+67.8%) |
Sep 2008 | - | -$17.16M(+2.9%) | -$34.54M(-35.1%) |
Jun 2008 | - | -$16.68M(+28.6%) | -$53.19M(-17.2%) |
Mar 2008 | - | -$12.96M(-205.7%) | -$64.24M(-21.7%) |
Dec 2007 | -$82.07M | $12.26M(-134.2%) | -$82.07M(-34.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2007 | - | -$35.81M(+29.1%) | -$124.42M(+9.9%) |
Jun 2007 | - | -$27.73M(-9.9%) | -$113.16M(+6.8%) |
Mar 2007 | - | -$30.79M(+2.3%) | -$105.99M(+13.9%) |
Dec 2006 | -$93.06M(-166.5%) | -$30.09M(+22.6%) | -$93.06M(-158.1%) |
Sep 2006 | - | -$24.55M(+19.4%) | $160.22M(+3.8%) |
Jun 2006 | - | -$20.56M(+15.1%) | $154.32M(+5.3%) |
Mar 2006 | - | -$17.86M(-108.0%) | $146.54M(+4.7%) |
Dec 2005 | $139.93M(+566.1%) | $223.19M(-832.9%) | $139.93M(-285.6%) |
Sep 2005 | - | -$30.45M(+7.5%) | -$75.38M(+49.2%) |
Jun 2005 | - | -$28.34M(+15.7%) | -$50.53M(+62.8%) |
Mar 2005 | - | -$24.48M(-410.3%) | -$31.04M(-247.8%) |
Dec 2004 | $21.01M(-124.1%) | $7.89M(-240.8%) | $21.01M(+7070.0%) |
Sep 2004 | - | -$5.60M(-36.7%) | $293.00K(-101.8%) |
Jun 2004 | - | -$8.85M(-132.1%) | -$16.15M(-51.3%) |
Mar 2004 | - | $27.57M(-314.9%) | -$33.18M(-61.8%) |
Dec 2003 | -$87.05M(-23.3%) | -$12.82M(-41.8%) | -$86.84M(-18.5%) |
Sep 2003 | - | -$22.05M(-14.8%) | -$106.60M(-6.9%) |
Jun 2003 | - | -$25.88M(-0.8%) | -$114.56M(-1.6%) |
Mar 2003 | - | -$26.09M(-19.9%) | -$116.40M(+2.6%) |
Dec 2002 | -$113.50M(+42.6%) | -$32.58M(+8.6%) | -$113.50M(+4.4%) |
Sep 2002 | - | -$30.01M(+8.2%) | -$108.70M(+8.2%) |
Jun 2002 | - | -$27.72M(+19.6%) | -$100.47M(+12.4%) |
Mar 2002 | - | -$23.18M(-16.5%) | -$89.41M(+12.3%) |
Dec 2001 | -$79.61M(+281.7%) | -$27.78M(+27.6%) | -$79.61M(+32.0%) |
Sep 2001 | - | -$21.77M(+30.7%) | -$60.32M(+14.1%) |
Jun 2001 | - | -$16.67M(+24.5%) | -$52.87M(+35.4%) |
Mar 2001 | - | -$13.38M(+57.6%) | -$39.05M(+17.5%) |
Dec 2000 | -$20.86M(+2.2%) | -$8.49M(-40.7%) | -$33.22M(+35.4%) |
Sep 2000 | - | -$14.33M(+405.2%) | -$24.52M(+70.4%) |
Jun 2000 | - | -$2.84M(-62.4%) | -$14.39M(-24.5%) |
Mar 2000 | - | -$7.55M(-3877.0%) | -$19.05M(-10.1%) |
Dec 1999 | -$20.40M(+114.7%) | $200.00K(-104.8%) | -$21.20M(-20.6%) |
Sep 1999 | - | -$4.20M(-44.0%) | -$26.70M(+10.3%) |
Jun 1999 | - | -$7.50M(-22.7%) | -$24.20M(+59.2%) |
Mar 1999 | - | -$9.70M(+83.0%) | -$15.20M(+60.0%) |
Dec 1998 | -$9.50M(+2.2%) | -$5.30M(+211.8%) | -$9.50M(+17.3%) |
Sep 1998 | - | -$1.70M(-213.3%) | -$8.10M(+24.6%) |
Jun 1998 | - | $1.50M(-137.5%) | -$6.50M(-38.1%) |
Mar 1998 | - | -$4.00M(+2.6%) | -$10.50M(+11.7%) |
Dec 1997 | -$9.30M(-17.0%) | -$3.90M(+3800.0%) | -$9.40M(+11.9%) |
Sep 1997 | - | -$100.00K(-96.0%) | -$8.40M(-25.0%) |
Jun 1997 | - | -$2.50M(-13.8%) | -$11.20M(+2.8%) |
Mar 1997 | - | -$2.90M(0.0%) | -$10.90M(-2.7%) |
Dec 1996 | -$11.20M(+558.8%) | -$2.90M(0.0%) | -$11.20M(+15.5%) |
Sep 1996 | - | -$2.90M(+31.8%) | -$9.70M(+27.6%) |
Jun 1996 | - | -$2.20M(-31.3%) | -$7.60M(+46.2%) |
Mar 1996 | - | -$3.20M(+128.6%) | -$5.20M(+108.0%) |
Dec 1995 | -$1.70M(-93.2%) | -$1.40M(+75.0%) | -$2.50M(-50.0%) |
Sep 1995 | - | -$800.00K(-500.0%) | -$5.00M(-26.5%) |
Jun 1995 | - | $200.00K(-140.0%) | -$6.80M(-57.5%) |
Mar 1995 | - | -$500.00K(-87.2%) | -$16.00M(-36.0%) |
Dec 1994 | -$25.00M(-30.0%) | -$3.90M(+50.0%) | -$25.00M(-20.4%) |
Sep 1994 | - | -$2.60M(-71.1%) | -$31.40M(-15.8%) |
Jun 1994 | - | -$9.00M(-5.3%) | -$37.30M(-0.3%) |
Mar 1994 | - | -$9.50M(-7.8%) | -$37.40M(+2.7%) |
Dec 1993 | -$35.70M(+119.0%) | -$10.30M(+21.2%) | -$36.40M(+15.2%) |
Sep 1993 | - | -$8.50M(-6.6%) | -$31.60M(+12.1%) |
Jun 1993 | - | -$9.10M(+7.1%) | -$28.20M(+27.6%) |
Mar 1993 | - | -$8.50M(+54.5%) | -$22.10M(+34.8%) |
Dec 1992 | -$16.30M(+85.2%) | -$5.50M(+7.8%) | -$16.40M(+14.7%) |
Sep 1992 | - | -$5.10M(+70.0%) | -$14.30M(+24.3%) |
Jun 1992 | - | -$3.00M(+7.1%) | -$11.50M(+11.7%) |
Mar 1992 | - | -$2.80M(-17.6%) | -$10.30M(+87.3%) |
Dec 1991 | -$8.80M(+193.3%) | -$3.40M(+47.8%) | -$5.50M(-39.6%) |
Sep 1991 | - | -$2.30M(+27.8%) | -$9.10M(+65.5%) |
Jun 1991 | - | -$1.80M(-190.0%) | -$5.50M(+120.0%) |
Mar 1991 | - | $2.00M(-128.6%) | -$2.50M(-24.2%) |
Dec 1990 | -$3.00M | -$7.00M(-638.5%) | -$3.30M(-189.2%) |
Sep 1990 | - | $1.30M(+8.3%) | $3.70M(+54.2%) |
Jun 1990 | - | $1.20M(0.0%) | $2.40M(+100.0%) |
Mar 1990 | - | $1.20M | $1.20M |
FAQ
- What is Regeneron Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
- What is Regeneron Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Regeneron Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?
What is Regeneron Pharmaceuticals annual EBITDA?
The current annual EBITDA of REGN is $5.32B
What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual EBITDA is $9.67B
What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, REGN annual EBITDA has changed by +$624.70M (+13.31%)
What is Regeneron Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of REGN is $1.04B
What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly EBITDA is $3.84B
What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, REGN quarterly EBITDA has changed by +$209.70M (+25.24%)
What is Regeneron Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of REGN is $5.53B
What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM EBITDA is $9.67B
What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, REGN TTM EBITDA has changed by +$979.00M (+21.52%)